Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004-2022.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Graier Thomas, Salmhofer Wolfgang, Jonak Constanze, Weger Wolfgang, Zikeli Claudia, Gruber Barbara, Sator Paul, Prillinger Knut, Mlynek Alexander, Schütz-Bergmayr Martina, Richter Leo, Ratzinger Gudrun, Sassmann Christoph, Painsi Clemens, Häring Nina, Wippel-Slupetzky Katharina, Skvara Hans, Trattner Hannes, Inzinger Martin, Bangert Christina, Ellersdorfer Christina, Falkensteiner Katharina, Sadoghi Birgit, Gruber-Wackernagel Alexandra, Hofer Angelika, Legat Franz, Lange-Asschenfeldt Bernhard, Schmuth Matthias, Vujic Igor, Hötzenecker Wolfram, Saxinger Werner, Müllegger Robert, Quehenberger Franz, Wolf Peter
Аннотация
PATIENTS AND METHODS: Patient characteristics and the first-year treatment effectiveness in biologic-naive patients have been analyzed since 2004 until now, irrespective of treatment switches.
RESULTS: Data from 2,729 patients were eligible for this analysis. The proportion of female patients increased significantly over the years from 29.9% to 36.2% (p < 0.028), while the number of patients with psoriatic arthritis declined from 36.6% to 30.0% (p < 0.001). Moreover, the duration of psoriatic disease and PASI at the start of the treatment significantly decreased. Last observation carrief forward (LOCF) analysis indicated that PASI 90 response increased from 18.9 to 44.6% at 3 months and from 32.9 to 66.8% at 12 months after treatment started. Similary, the PASI ≤ 3 rates increased from 33.2% to 66.0% at 3 months and from 41.9% to 78.9% at 12 months after the treatment started.
CONCLUSIONS: The continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes. Though one out of three to five patients, depending on the endpoint selected, nowadays still does not achieve an entirely satisfactory treatment response (i.e., PASI 90 or PASI ≤ 3).